Technik der Peritonektomie sowie der hyperthermen intraperitonealen Chemotherapie

 

 Buy Article Permissions and Reprints

Zusammenfassung

Die Behandlung der Peritonealkarzinose stellt eine große Herausforderung in der Therapie gastro­intestinaler Tumore dar. Ein multimoda­ler The­rapieansatz mit chirurgisch kompletter makroskopischer Zytoreduktion und hyperthermer intraperitonealer Chemotherapie kann bei ausgewählten Patienten zu einer Verbesserung der Prognose führen. Die komplette makrosko­pische Zytoreduktion, bestehend aus parietaler und viszeraler Peritonektomie, oft in Form einer multiviszeralen Resektion, ist operationstechnisch anspruchsvoll und sollte nur von erfah­renen Viszeralchirurgen durchgeführt werden. Zugleich erfordert die hypertherme intraperitoneale Chemotherapie einen großen logistischen Aufwand. Besonders unter Berücksichtigung der langen Lernkurve, die diese Behandlungsform aufweist, sollte die Kombinationstherapie nur in speziellen Zentren angeboten werden. Unter optimalen Voraussetzungen ist die Behandlung mit vertretbarer Morbidität und niedriger Letalität durchführbar. Patienten mit Peritonealkarzinose sollten bezüglich dieser Therapieoption interdisziplinär evaluiert und am besten im Rahmen von Studien behandelt werden.

Abstract

The treatment of peritoneal carcinomatosis represents a challenge in the therapy for gastrointestinal cancer. A multimodal approach with complete surgical cytoreduction and hyperthermic intraperitoneal chemotherapy can improve the prognosis in selected patients. Complete surgical cytoreduction, consisting of partietal and visceral peritonectomy, is a sophisticated procedure, frequently requiring multivisceral resections and should only be performed by experienced visceral surgeons. In addition, hyperthermic intraperitoneal chemotherapy is of some complexity. Furthermore, regarding the learning curve for this procedure, combined treatment should only be performed in specialised centres. Under optimal conditions, the therapy can be carried out with reasonable morbidity and mortality rates. Patients with peritoneal carcinomatosis should be evaluated by an interdisciplinary team concerning this multimodal therapy option and, if applicable, they should be referred to therapy within the framework of clinical studies.

Literatur

• 1 Elias D, Matsuhisa T, Sideris L et al. Heated intra-operative intraperitoneal oxaliplatin plus irinotecan after complete resection of peritoneal carcinomatosis: pharmacokinetics, tissue distribution and tolerance.  Ann Oncol. 2004;  15 1558-1565
  CrossrefPubMedGoogle Scholar
• 2 Esquivel J, Sticca R, Sugarbaker P et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal surface malignancies of colonic origin: a consensus statement. Society of Surgical Oncology.  Ann Surg Oncol. 2007;  14 128-133
  PubMedGoogle Scholar
• 3 Glehen O, Kwiatkowski F, Sugarbaker P H et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study.  J Clin Oncol. 2004;  22 3284-3292
  CrossrefPubMedGoogle Scholar
• 4 Glehen O, Osinsky D, Cotte E et al. Intraperitoneal chemohyperthermia using a closed abdominal procedure and cytoreductive surgery for the treatment of peritoneal carcinomatosis: morbidity and mortality analysis of 216 consecutive procedures.  Ann Surg Oncol. 2003;  10 863-869
  CrossrefPubMedGoogle Scholar
• 5 McQuellon R P, Danhauer S C, Russell G B et al. Monitoring health outcomes following cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis.  Ann Surg Oncol. 2007;  14 1105-1113
  CrossrefPubMedGoogle Scholar
• 6 Moran B J, Mukherjee A, Sexton R. Operability and early outcome in 100 consecutive laparotomies for peritoneal malignancy.  Br J Surg. 2006;  93 100-104
  CrossrefPubMedGoogle Scholar
• 7 Pilati P, Mocellin S, Rossi C R et al. Cytoreductive surgery combined with hyperthermic intraperitoneal intraoperative chemotherapy for peritoneal carcinomatosis arising from colon adenocarcinoma.  Ann Surg Oncol. 2003;  10 508-513
  CrossrefPubMedGoogle Scholar
• 8 Russell A H, Tong D, Dawson L E et al. Adenocarcinoma of the proximal colon. Sites of initial dissemination and patterns of recurrence following surgery alone.  Cancer. 1984;  53 360-367
  CrossrefPubMedGoogle Scholar
• 9 Sadeghi B, Arvieux C, Glehen O et al. Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study.  Cancer. 2000;  88 358-363
  CrossrefPubMedGoogle Scholar
• 10 Schmidt C, Creutzenberg M, Piso P et al. Perioperative anaesthetic management of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy.  Anaesthesia. 2008;  63 389-395
  CrossrefPubMedGoogle Scholar
• 11 Schmidt U, Dahlke M H, Klempnauer J et al. Perioperative morbidity and quality of life in long-term survivors following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.  Eur J Surg Oncol. 2005;  31 53-58
  CrossrefPubMedGoogle Scholar
• 12 Shen P, Hawksworth J, Lovato J et al. Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy with mitomycin C for peritoneal carcinomatosis from nonappendiceal colorectal carcinoma.  Ann Surg Oncol. 2004;  11 178-186
  CrossrefPubMedGoogle Scholar
• 13 Smeenk R M, Verwaal V J, Zoetmulder F A. Learning curve of combined modality treatment in peritoneal surface disease.  Br J Surg. 2007;  94 1408-1414
  CrossrefPubMedGoogle Scholar
• 14 Stephens A D, Alderman R, Chang D et al. Morbidity and mortality analysis of 200 treatments with cytoreductive surgery and hyperthermic intraoperative intraperitoneal chemotherapy using the coliseum technique.  Ann Surg Oncol. 1999;  6 790-796
  CrossrefPubMedGoogle Scholar
• 15 Sugarbaker P H. Peritonectomy procedures.  Ann Surg. 1995;  221 29-42
  CrossrefPubMedGoogle Scholar
• 16 Sugarbaker P H. Management of peritoneal-surface malignancy: the surgeon’s role.  Langenbecks Arch Surg. 1999;  384 576-587
  CrossrefPubMedGoogle Scholar
• 17 Sugarbaker P H. Cytoreductive surgery and peri-operative intraperitoneal chemotherapy as a curative approach to pseudomyxoma peritonei syndrome.  Eur J Surg Oncol. 2001;  27 239-243
  CrossrefPubMedGoogle Scholar
• 18 Sugarbaker P H. Cytoreduction including total gastrectomy for pseudomyxoma peritonei.  Br J Surg. 2002;  89 208-212
  PubMedGoogle Scholar
• 19 Sugarbaker P H. Are there curative options to peritoneal carcinomatosis?.  Ann Surg. 2005;  242 748-750
  PubMedGoogle Scholar
• 20 Sugarbaker P H, Ronnett B M, Archer A et al. Pseudomyxoma peritonei syndrome.  Adv Surg. 1996;  30 233-280
  PubMedGoogle Scholar
• 21 Verwaal V J, van Ruth S, de Bree E et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer.  J Clin Oncol. 2003;  21 3737-3743
  CrossrefPubMedGoogle Scholar
• 22 Verwaal V J, van Ruth S, Witkamp A et al. Long-term survival of peritoneal carcinomatosis of colorectal origin.  Ann Surg Oncol. 2005;  12 65-71
  CrossrefPubMedGoogle Scholar
• 23 Yan T D, Black D, Sugarbaker P H et al. A systematic review and meta-analysis of the randomized controlled trials on adjuvant intraperitoneal chemotherapy for resectable gastric cancer.  Ann Surg Oncol. 2007;  14 2702-2713
  CrossrefPubMedGoogle Scholar
• 24 Yan T D, Brun E A, Cerruto C A et al. Prognostic indicators for patients undergoing cytoreductive surgery and perioperative intraperitoneal chemotherapy for diffuse malignant peritoneal mesothelioma.  Ann Surg Oncol. 2007;  14 41-49
  PubMedGoogle Scholar
• 25 Yan T D, Links M, Fransi S et al. Learning curve for cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal surface malignancy – a journey to becoming a Nationally Funded Peritonectomy Center.  Ann Surg Oncol. 2007;  14 2270-2280
  CrossrefPubMedGoogle Scholar

Prof. Dr. P. Piso

Klinik und Poliklinik für Chirurgie ·Universitätsklinik Regensburg

Franz-Josef-Strauss-Allee 11

93053 Regensburg

Deutschland

Phone: +49 / 9 41 / 9 44 68 09

Email: pompiliu.piso@klinik.uni-regensburg.de